TAC 001
Alternative Names: CD22 targeting TRAAC - Tallac Therapeutics; TAAC-001Latest Information Update: 16 Jun 2025
At a glance
- Originator Tallac Therapeutics
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Oligonucleotides
- Mechanism of Action Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 25 Apr 2025 Efficacy, pharmacokinetic and adverse events data from a phase I/II trial presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 10 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer released by Tallac Therapeutics
- 05 Apr 2024 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)